Issue : Clinical Pharmacist, March 2019, Vol 11, No 3
The Royal Pharmaceutical Society Panel of Fellows will be holding its next meeting in May 2019. Nominations for Society Fellowship must be received by the Secretary of the Panel of Fellows by 17 April 2019 to be considered at this meeting.
Sulfonylureas and basal insulin confer an increased risk of cardiovascular events compared with newer second-line medicines for type 2 diabetes mellitus, research has found.
Existing medicines for physical conditions such as diabetes and hypertension could be used to treat serious mental illness, concluded the authors of a recent study in JAMA Psychiatry.